Actinium Pharmaceuticals Inc. (Delaware)
| AMEX: ATNM | Healthcare / Biotechnology / USA |
| 6.30 | +0.0100 | +0.16% | Vol 200.73K | 1Y Perf -15.00% |
| Sep 22nd, 2023 16:00 DELAYED |
| BID | 6.27 | ASK | 6.30 | ||
| Open | 6.34 | Previous Close | 6.29 | ||
| Pre-Market | - | After-Market | 6.30 | ||
| - - | - -% |
| Target Price | 31.40 | Analyst Rating | Strong Buy 1.40 | |
| Potential % | 398.41 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★+ 49.69 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 4.65 | Earnings Rating | Sell | |
| Market Cap | 170.08M | Earnings Date | 13th Nov 2023 | |
| Alpha | 0.00 | Standard Deviation | 0.24 | |
| Beta | 0.38 |
Today's Price Range 6.226.50 | 52W Range 5.8715.12 | 5 Year PE Ratio Range -2.70-2.10 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -4.26% | ||
| 1 Month | 5.18% | ||
| 3 Months | -16.11% | ||
| 6 Months | -31.52% | ||
| 1 Year | -15.00% | ||
| 3 Years | -29.29% | ||
| 5 Years | -71.62% | ||
| 10 Years | -96.21% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -50.95 | |||
ROE last 12 Months | -43.63 | |||
ROA (5Y Avg) | -18.41 | |||
ROA last 12 Months | -32.25 | |||
ROC (5Y Avg) | -100.21 | |||
ROC last 12 Months | -39.93 | |||
Return on invested Capital Q | -12.67 | |||
Return on invested Capital Y | -10.41 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -7.60 | ||||
| 3.53 | ||||
| 232.07 | ||||
| 20.20 | ||||
| 15.70 | ||||
| 0.49 | ||||
| 3.53 | ||||
| 2.80 | ||||
| 142.56M | ||||
| Forward PE | -4.63 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 13.40 | ||||
| 13.60 | ||||
| 0.03 | ||||
| 0.04 | ||||
| - | ||||
| Leverage Ratio | 1.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -2 930.80 | ||||
| -2 866.70 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.03M | ||||
| 0.04 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.50 | -0.58 | -16.00 |
| Q01 2023 | -0.42 | -0.43 | -2.38 |
| Q04 2022 | - | -0.42 | - |
| Q03 2022 | -0.30 | -0.38 | -26.67 |
| Q02 2022 | -0.23 | -0.33 | -43.48 |
| Q01 2022 | -0.31 | -0.23 | 25.81 |
| Q03 2021 | -0.29 | -0.30 | -3.45 |
| Q02 2021 | -0.30 | -0.25 | 16.67 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.54 | -8.00 | Negative |
| 12/2023 QR | -0.49 | 5.77 | Positive |
| 12/2023 FY | -2.05 | -7.89 | Negative |
| 12/2024 FY | -1.42 | -7.58 | Negative |
| Next Report Date | 13th Nov 2023 |
| Estimated EPS Next Report | -0.54 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 200.73K |
| Shares Outstanding | 27.00K |
| Shares Float | 23.96M |
| Trades Count | 1.97K |
| Dollar Volume | 1.26M |
| Avg. Volume | 204.57K |
| Avg. Weekly Volume | 206.65K |
| Avg. Monthly Volume | 199.03K |
| Avg. Quarterly Volume | 208.04K |
Actinium Pharmaceuticals Inc. (Delaware) (AMEX: ATNM) stock closed at 6.3 per share at the end of the most recent trading day (a 0.16% change compared to the prior day closing price) with a volume of 200.73K shares and market capitalization of 170.08M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 25 people. Actinium Pharmaceuticals Inc. (Delaware) CEO is Sandesh Seth.
The one-year performance of Actinium Pharmaceuticals Inc. (Delaware) stock is -15%, while year-to-date (YTD) performance is -40.85%. ATNM stock has a five-year performance of -71.62%. Its 52-week range is between 5.87 and 15.12, which gives ATNM stock a 52-week price range ratio of 4.65%
Actinium Pharmaceuticals Inc. (Delaware) currently has a PE ratio of -7.60, a price-to-book (PB) ratio of 3.53, a price-to-sale (PS) ratio of 232.07, a price to cashflow ratio of 20.20, a PEG ratio of -, a ROA of -32.25%, a ROC of -39.93% and a ROE of -43.63%. The company’s profit margin is -%, its EBITDA margin is -2 866.70%, and its revenue ttm is $1.03 Million , which makes it $0.04 revenue per share.
Of the last four earnings reports from Actinium Pharmaceuticals Inc. (Delaware), there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.54 for the next earnings report. Actinium Pharmaceuticals Inc. (Delaware)’s next earnings report date is 13th Nov 2023.
The consensus rating of Wall Street analysts for Actinium Pharmaceuticals Inc. (Delaware) is Strong Buy (1.4), with a target price of $31.4, which is +398.41% compared to the current price. The earnings rating for Actinium Pharmaceuticals Inc. (Delaware) stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Actinium Pharmaceuticals Inc. (Delaware) has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Actinium Pharmaceuticals Inc. (Delaware) has a Sell technical analysis rating based on Technical Indicators (ADX : 23.47, ATR14 : 0.35, CCI20 : -33.40, Chaikin Money Flow : -0.14, MACD : -0.06, Money Flow Index : 46.30, ROC : -4.83, RSI : 45.60, STOCH (14,3) : 16.27, STOCH RSI : 0.29, UO : 43.87, Williams %R : -83.73), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Actinium Pharmaceuticals Inc. (Delaware) in the last 12-months were:
Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
CEO: Sandesh Seth
Telephone: +1 646 677-3870
Address: 275 Madison Avenue, New York 10016, NY, US
Number of employees: 25
TipRanks News for ATNM
Wed, 16 Aug 2023 16:00 GMT Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Plus Therapeutics (PSTV)
- TipRanks. All rights reserved.
